CYTH Cyclo Therapeutics Inc.: חוב להון עצמי

Cyclo Therapeutics (CYTH) minimizes capital expenditures by outsourcing drug production and testing to external contractors. This price chart demonstrates a total debt-to-equity ratio of 0.00. The business relies on Trappsol Cyclo, which aims to become the gold standard therapy for Niemann-Pick disease. Due to its unique mechanism for clearing cholesterol from the body, the company possesses significant pricing power.

By advancing independent medical research, Cyclo Therapeutics (CYTH) relies on stable demand, as reflected in its total debt-to-equity ratio. This metric compares total liabilities to shareholders' equity, allowing investors to assess the degree of financial leverage and the company's reliance on borrowed funds. Low indebtedness in this sector confirms high autonomy and the business's resilience to external shocks.